THE APPLICATION OF sIgE/sIgG4 AND IFN ‐γ IN INFANTILE ALLERGY MARCH

Source: Respirology - Category: Respiratory Medicine Tags: Clinical Allergy & Immunology / Paediatric Lung Disease Source Type: research

Related Links:

CONCLUSIONS: Severe SE, not outcomes, was the most decisive attribute determining future HCRCT participation. Particular attention should be paid to providing clear information, in particular on severe SE, to potential participants. Immunotherapy would appear to be the best HCRCT candidate for both PLWH and physicians. However, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former. PMID: 32077248 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Even if children ultimately get caught up on their vaccines after early delays, they remain susceptible to vaccine-preventable diseases for longer right when they're most vulnerable to complications.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
The Houston ENT&Allergy Clinic not only slashed its no-show rates, but also increased its referral conversion by 35%, which translated to an additional $500,000 in annual revenue.
Source: Healthcare ITNews Videos - Category: Information Technology Tags: Patient Engagement Telehealth Source Type: video
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
Condition:   Corona Virus Infection Interventions:   Other: Placebo;   Drug: Remdesivir Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 20 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Susann Forkel, Timo Buhl
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 6 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Khalaf Kridin, Yael Renert-Yuval, Emma Guttman-Yassky, Arnon D. CohenBackgroundEvidence of TH1/IFN-γ overactivation as a major pathogenic driver somewhat conflicts with data supporting robust allergic background in patients with alopecia areata (AA). Previous investigations of immunological dysregulations show that both TH1- and TH2-related markers are overexpressed in AA. Clinical correlations in large populations may shed light on the immune pathways most likely to result in the clinical p...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Pediatrics